Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer

Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer

Paris (France), 26 January 2018 – Ipsen (Euronext: IPN; ADR: IPSEY) has announced that Sotirios
G. Stergiopoulos, MD, has been appointed as Chief Medical Officer.
Dr Stergiopoulos joined Ipsen in January 2017 as Senior Vice President, Head of Global Medical Affairs (GMA) and will retain this
position in addition to the role as the new Chief Medical Officer within the company. Dr Stergiopoulos reports to Alexandre Lebeaut, MD, Executive Vice-President R&D and Chief Scientific Officer.

Dr Lebeaut commented, “Sotirios has extensive experience in directing global medical affairs
strategies and a strong expertise in oncology drug development that includes chemotherapy,
immunology drugs and targeted agents across various tumor indications. We are delighted to appoint
him to an expanded role through which he will make the voice of the patient heard at the highest levels
of the organization and represent the company externally as its primary medical representative.

Prior to joining Ipsen, Sotirios was Vice President, Head of Global Medical Affairs Oncology at Baxalta (now Shire, Cambridge, MA), Executive Medical Director Oncology US Medical Affairs at Celgene Corporation (Summit, NJ), Senior Global Brand Medical Director Oncology at Novartis Pharmaceuticals (East Hanover, NJ) and Director Medical Affairs Oncology at Bayer Healthcare
(Montville, NJ).

Dr. Stergiopoulos added, “I am delighted to take on this leading role at Ipsen. This is an exciting
time for Ipsen with significant growth and evolution. Together with our experienced leadership team,
I look forward to helping our company continue to bring innovative new medicines to our patients.

Dr. Stergiopoulos is a physician executive with significant experience in the Pharmaceutical/Biotech industry, especially in Oncology. He has held appointments as an Attending Physician and trainee in institutions such as Albert Einstein College of Medicine, Harvard Medical School and the National Institutes of Health. He holds a Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from The Johns Hopkins University and a Medical Degree from Poznan University of Medical
Sciences (Poland). Sotirios is a Fellow of the American College of Physicians, the New York Academy of Medicine as well as the Royal Society of Medicine (UK). He is also a Member of the American Association for Cancer Research and of the American Society of Clinical Oncology.
In October 2017 Dr. Stergiopoulos was appointed President of the Board of Governors for the Accreditation Council for Medical Affairs (ACMA); a body whose mission is to establish, certify, and maintain the competencies of qualified medical and scientific professionals who have a focus in Medical Affairs within the pharmaceutical & biotechnology industries.

Related Press Releases